Literature DB >> 17325738

Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer.

Changqing Zhao1, Loganath Annamalai, Changfa Guo, Narasimhan Kothandaraman, Stephen Chee Liang Koh, Huoming Zhang, Arijit Biswas, Mahesh Choolani.   

Abstract

OBJECTIVE: This study was conducted to evaluate the prognostic significance of haptoglobin levels in the overall survival of patients presenting with various stages of epithelial ovarian cancer.
MATERIALS AND METHODS: We employed an in-house sandwich enzyme-linked immunosorbent assay method to determine the concentrations of preoperative haptoglobin and C-reactive protein (CRP) in sera samples obtained from 66 malignant tumors, 60 benign tumors, and 10 normal healthy women.
RESULTS: Levels of serum haptoglobin significantly correlated with tumor type (P < .001) and International Federation of Gynecology and Obstetrics stage (P < .05). A significant correlation was observed between clinical stage and patient survival (r = 5.99, P = .026). Our data also indicated that elevated serum haptoglobin levels were associated with poor outcome for overall survival using both univariate and multivariate analyses (P = .048 and P = .036 respectively). Using Pearson's correlation, we have noted that serum CRP concentrations significantly correlated with haptoglobin levels (r(2) = 0.22, P < .001). Immunohistochemical findings and Western blot analyses were compatible with sera levels of haptoglobin in which a higher intensity of staining occurred in late-stage epithelial ovarian cancers.
CONCLUSION: This study provides evidence that preoperative serum levels of haptoglobin could serve as an independent prognostic factor in patients presenting with epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325738      PMCID: PMC1803031          DOI: 10.1593/neo.06619

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  31 in total

Review 1.  Regulation of matrix metalloproteinase expression in tumor invasion.

Authors:  J Westermarck; V M Kähäri
Journal:  FASEB J       Date:  1999-05       Impact factor: 5.191

2.  Expression of haptoglobin in human keratinocytes and Langerhans cells.

Authors:  H Wang; X-H Gao; Y-K Wang; P Li; C-D He; Y Xie; H-D Chen
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

3.  Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors:  R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

4.  Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.

Authors:  W Dobryszycka; J Gerber; J Zuwała-Jagiełło; M Ujec
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1991       Impact factor: 4.291

5.  Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.

Authors:  Antonio Macciò; Clelia Madeddu; Daniela Massa; Maria C Mudu; Maria R Lusso; Giulia Gramignano; Roberto Serpe; Gian Benedetto Melis; Giovanni Mantovani
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

6.  Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation.

Authors:  Noriko Okuyama; Yoshihito Ide; Miyako Nakano; Tsutomu Nakagawa; Kanako Yamanaka; Kenta Moriwaki; Kohei Murata; Hiroaki Ohigashi; Shigekazu Yokoyama; Hidetoshi Eguchi; Osamu Ishikawa; Toshifumi Ito; Michio Kato; Akinori Kasahara; Sunao Kawano; Jianguo Gu; Naoyuki Taniguchi; Eiji Miyoshi
Journal:  Int J Cancer       Date:  2006-06-01       Impact factor: 7.396

7.  Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary.

Authors:  W Dobryszycka; I Katnik-Prastowska; J Gerber; K Lemańska; K Utko; K Rozdolski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1999       Impact factor: 4.291

8.  Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.

Authors:  Nuzhat Ahmed; Karen T Oliva; Gillian Barker; Peter Hoffmann; Shane Reeve; Ian A Smith; Michael A Quinn; Greg E Rice
Journal:  Proteomics       Date:  2005-11       Impact factor: 3.984

9.  Ascites levels of haptoglobin in patients with ovarian cancer.

Authors:  S A Elg; L F Carson; J M Fowler; L B Twiggs; M M Moradi; S Ramakrishnan
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

10.  Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer.

Authors:  S Thompson; B M Cantwell; K L Matta; G A Turner
Journal:  Cancer Lett       Date:  1992-08-14       Impact factor: 8.679

View more
  31 in total

1.  The changes of serum proteome and tissular pathology in mouse induced by botulinum toxin E injection.

Authors:  J F Wang; X Y Mao; C Zhao
Journal:  Mol Biol Rep       Date:  2014-01-24       Impact factor: 2.316

2.  Identification of novel serum biomarkers in child nephroblastoma using proteomics technology.

Authors:  Qian Zhang; Jiaxiang Wang; Rui Dong; Shaobo Yang; Shu Zheng
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

3.  Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry.

Authors:  You-Kang Chang; Yu-Heng Lai; Yen Chu; Ming-Cheng Lee; Chun-Yao Huang; Semon Wu
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 4.  Glycans and glycoproteins as specific biomarkers for cancer.

Authors:  Muchena J Kailemia; Dayoung Park; Carlito B Lebrilla
Journal:  Anal Bioanal Chem       Date:  2016-09-03       Impact factor: 4.142

5.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells.

Authors:  Kutlu G Elpek; Viviana Cremasco; Hua Shen; Christopher J Harvey; Kai W Wucherpfennig; Daniel R Goldstein; Paul A Monach; Shannon J Turley
Journal:  Cancer Immunol Res       Date:  2014-03-31       Impact factor: 11.151

7.  Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum.

Authors:  Kristin Lm Boylan; John D Andersen; Lorraine B Anderson; LeeAnn Higgins; Amy Pn Skubitz
Journal:  Proteome Sci       Date:  2010-06-14       Impact factor: 2.480

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma.

Authors:  Mee Lee Looi; Saiful Anuar Karsani; Mariati Abdul Rahman; Ahmad Zailani Hatta Mohd Dali; Siti Aishah Md Ali; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  J Biosci       Date:  2009-12       Impact factor: 1.826

10.  Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.

Authors:  Yeng Chen; Boon-Kiong Lim; Onn H Hashim
Journal:  J Hematol Oncol       Date:  2009-08-27       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.